ATE358668T1 - Drogen zur behandlung maligner tumoren - Google Patents

Drogen zur behandlung maligner tumoren

Info

Publication number
ATE358668T1
ATE358668T1 AT00973329T AT00973329T ATE358668T1 AT E358668 T1 ATE358668 T1 AT E358668T1 AT 00973329 T AT00973329 T AT 00973329T AT 00973329 T AT00973329 T AT 00973329T AT E358668 T1 ATE358668 T1 AT E358668T1
Authority
AT
Austria
Prior art keywords
malignant tumors
drugs used
treat malignant
compounds
formula
Prior art date
Application number
AT00973329T
Other languages
English (en)
Inventor
Gunnar Hedlund
Karl Jansson
Stig Joensson
Anders Bjoerk
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9903838A external-priority patent/SE9903838D0/xx
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Application granted granted Critical
Publication of ATE358668T1 publication Critical patent/ATE358668T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00973329T 1999-10-25 2000-10-24 Drogen zur behandlung maligner tumoren ATE358668T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16140799P 1999-10-25 1999-10-25
SE9903838A SE9903838D0 (sv) 1999-10-25 1999-10-25 Novel compounds
US21281600P 2000-06-21 2000-06-21
SE0002320A SE0002320D0 (sv) 1999-10-25 2000-06-21 Malignant tumors

Publications (1)

Publication Number Publication Date
ATE358668T1 true ATE358668T1 (de) 2007-04-15

Family

ID=27484521

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00973329T ATE358668T1 (de) 1999-10-25 2000-10-24 Drogen zur behandlung maligner tumoren

Country Status (21)

Country Link
EP (1) EP1224172B1 (de)
JP (1) JP3950337B2 (de)
KR (2) KR100597938B1 (de)
AT (1) ATE358668T1 (de)
AU (1) AU775057B2 (de)
CA (1) CA2386775C (de)
CZ (1) CZ298534B6 (de)
DE (1) DE60034240T2 (de)
DK (1) DK1224172T3 (de)
EE (1) EE200200207A (de)
ES (1) ES2280258T3 (de)
HK (1) HK1049830A1 (de)
HR (1) HRP20020353A2 (de)
HU (1) HU229072B1 (de)
IL (2) IL148782A0 (de)
IS (1) IS2750B (de)
NO (1) NO323320B1 (de)
NZ (1) NZ518296A (de)
SE (1) SE0002320D0 (de)
UA (1) UA73748C2 (de)
WO (1) WO2001030758A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
PL1773816T3 (pl) 2004-06-24 2015-06-30 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą ATP
US7884208B2 (en) * 2005-10-19 2011-02-08 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
JP5409010B2 (ja) 2005-12-28 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
EP2035001B1 (de) 2006-06-12 2011-11-09 Teva Pharmaceutical Industries Limited Stabile laquinimod-zubereitungen
KR100916160B1 (ko) * 2007-02-21 2009-09-08 (주)바이오버드 약제학적 항암 조성물
EP2065380A1 (de) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Pyridonamid-Derivate als Focal-Adhesion-Kinase (FAK) Hemmer und deren Verwendung zur Behandlung von Krebs
SI2234485T1 (sl) 2007-12-20 2014-03-31 Teva Pharmaceutical Industries Ltd. Stabilni lakvinimodni pripravki
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
CN104311486A (zh) 2008-09-03 2015-01-28 泰华制药工业有限公司 2-羰基-1,2-二氢喹啉免疫功能调节剂
MX361711B (es) 2009-03-20 2018-12-14 Vertex Pharmaceuticals Incorporated Star Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quistica.
US8962598B2 (en) * 2010-10-14 2015-02-24 Immunahr Ab 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AHR activators
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2537517A1 (de) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-angereichertes 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluor-methyl)phenyl]-1,2-dihydrochinolin-3-carboxamid
CA2865519C (en) 2012-02-27 2018-01-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis
EA201590788A1 (ru) * 2012-11-07 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Аминные соли лахинимода
SG11201506409RA (en) 2013-03-14 2015-09-29 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
US9956212B2 (en) 2014-09-23 2018-05-01 Active Biotech Ab Quinoline carboxamides for use in the treatment of multiple myeloma
EP3204358B1 (de) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Cokristalle von modulatoren des transmembrankonduktanzregulators bei zystischer fibrose
EA031643B1 (ru) * 2014-11-19 2019-01-31 Эктив Байотек Аб Применение тасквинимода для лечения острого лимфобластного лейкоза и острого миелоидного лейкоза
WO2019074116A1 (ja) 2017-10-13 2019-04-18 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
CN115003665B (zh) * 2019-11-28 2024-11-08 拜耳公司 作为免疫活化的DGKα抑制剂的取代的氨基喹诺酮
BR112022016873A2 (pt) 2020-03-03 2022-10-25 Active Biotech Ab Combinação, kit, e, tasquinimod ou um sal farmaceuticamente aceitável do mesmo para uso no tratamento de mieloma múltiplo
JP2023527782A (ja) * 2020-05-21 2023-06-30 ステムシナジー セラピューティクス， インク． Ｎｏｔｃｈ阻害剤及びその使用
CA3204120A1 (en) 2021-01-18 2022-07-21 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
ES3048983T3 (en) 2021-05-25 2025-12-12 Active Biotech Ab A plurality of tasquinimod particles and use thereof
IL309486A (en) 2021-07-02 2024-02-01 Active Biotech Ab A pharmacy product containing tesquinimod and a method for evaluating the cleanliness of this product
AR126963A1 (es) 2021-09-13 2023-12-06 Lilly Co Eli Agonistas de ahr
TWI838849B (zh) * 2021-09-13 2024-04-11 美商美國禮來大藥廠 Ahr促效劑
EP4452946A4 (de) * 2021-12-20 2025-11-26 Univ Johns Hopkins Verbindungen zur behandlung von krebs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
GB2290786A (en) * 1994-06-30 1996-01-10 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives

Also Published As

Publication number Publication date
NO323320B1 (no) 2007-03-12
NO20021932L (no) 2002-06-21
HUP0203238A3 (en) 2003-05-28
WO2001030758A1 (en) 2001-05-03
KR100597938B1 (ko) 2006-07-06
CA2386775C (en) 2004-07-13
DK1224172T3 (da) 2007-08-13
HK1049830A1 (zh) 2003-05-30
UA73748C2 (en) 2005-09-15
JP2003512454A (ja) 2003-04-02
CA2386775A1 (en) 2001-05-03
ES2280258T3 (es) 2007-09-16
KR20020043646A (ko) 2002-06-10
HUP0203238A2 (hu) 2003-01-28
EE200200207A (et) 2003-06-16
IL148782A (en) 2007-05-15
SE0002320D0 (sv) 2000-06-21
KR20060054496A (ko) 2006-05-22
JP3950337B2 (ja) 2007-08-01
KR100674160B1 (ko) 2007-01-24
DE60034240D1 (de) 2007-05-16
IS6329A (is) 2002-04-02
NO20021932D0 (no) 2002-04-24
IL148782A0 (en) 2002-09-12
EP1224172A1 (de) 2002-07-24
CZ20021293A3 (cs) 2002-07-17
NZ518296A (en) 2003-06-30
AU775057B2 (en) 2004-07-15
IS2750B (is) 2011-08-15
HU229072B1 (en) 2013-07-29
DE60034240T2 (de) 2007-12-20
AU1185101A (en) 2001-05-08
CZ298534B6 (cs) 2007-10-31
EP1224172B1 (de) 2007-04-04
HRP20020353A2 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
ATE358668T1 (de) Drogen zur behandlung maligner tumoren
YU23202A (sh) Lekovi za tretman malignih tumora
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
IS2114B (is) Kínasólínafleiður til að meðhöndla æxli
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
SE9904505D0 (sv) Novel compounds
SE0104140D0 (sv) Novel Compounds
PL367682A1 (en) Dolastatin 10 derivatives
DE50310516D1 (de) Fredericamycin-derivate
BR0309355A (pt) 2-(2,6-diclorofenil)-diarilimidazóis
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
ATE233754T1 (de) Diphenyl-piperidin derivate
DE60301339D1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
BR0112807A (pt) Derivados de indol e sua aplicação como medicamento
MXPA04005809A (es) Inhibidores de proteinas quinasas.
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
SE9902551D0 (sv) Novel compounds
DE60123117D1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
BR0116123A (pt) Carbazóis antitumorais
AU6826700A (en) Ceramide analogs, process for their preparation and their use as antitumor agents
CY1106576T1 (el) Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας
SE0004827D0 (sv) Therapeutic compounds
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties